Jeremy Levin via YouTube
Ovid cuts its losses on controversial Angelman syndrome drug, making its crushing development halt permanent
After a turbulent couple of years, Ovid is officially doing away with a program it had once championed in the face of heavy analyst skepticism …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
